A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

A Phase I, Single-arm, Open-label, Multi-center Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GLR2037 in Patients With Metastatic Prostate Cancer

A Phase I Clinical Study of GLR2037 in Patients with Advanced Prostate Cancer

Study Overview

• Status: Not yet recruiting
• Conditions: Prostate Cancer
• Intervention / Treatment: Drug: GLR2037

• Study Type: Interventional
• Enrollment (Estimated): 65
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Yunda Zhuge; Phone Number: 13705398525; Email: zhugeyunda@ganlee.com

Study Locations

• China
  • Beijing, China
    • No.8 Nanfeng West 1st Street, Huoxian, Tongzhou District
    • Contact: Phone Number: 010-56456726; Email: zhugeyunda@ganlee.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion criteria:

1. Male, aged ≥ 18 years.
2. Histologically or cytologically confirmed adenocarcinoma of the prostate, without neuroendocrine or small cell features.
3. Metastatic bone or soft tissue lesions documented by imaging.
4. Prior surgical or medical castration.
5. Castrate level of testosterone at screening (≤ 50 ng/dL or 1.73 nmol/L).
6. Phase Ia and Ib: Prior treatment with at least one novel endocrine therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide, rezlutamide, etc.); patients in the dose-escalation phase of Phase Ia must have received at least one prior line of chemotherapy (e.g., docetaxel, cabazitaxel, etc.).
7. Evidence of disease progression during castration therapy in patients with metastatic prostate cancer at screening.
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
9. Adequate organ function meeting protocol-specified criteria.
10. Life expectancy ≥ 3 months.
11. Fertile male subjects and their partners must agree to use effective contraception (e.g., condoms) and refrain from donating sperm from the first dose of the study drug until 3 months after the last dose.
12. Willing to participate in this clinical trial, understand the study procedures, and have signed the informed consent form.

Exclusion Criteria:"1. Prior use of AR protein degraders. 2. Use of any other biological and/or immunological anti-tumor therapy (except castration therapy), targeted therapy, estrogen therapy, anti-androgen therapy, or other interventional investigational drug therapy; or receipt of systemic chemotherapy, systemic radiotherapy, or Chinese herbal/patent medicine with anti-tumor indications (as clearly stated in the package insert) within 4 weeks (or 5 half-lives, whichever is shorter) prior to the first dose; or receipt of nitrosoureas, bicalutamide, or nilutamide within 6 weeks (or 5 half-lives, whichever is shorter) prior to the first dose.

3. Subjects who have used bisphosphonates or RANKL inhibitors for the treatment of bone metastases or bone-related diseases within 2 weeks prior to the first dose.

4. Have received systemic immunosuppressive therapy within 2 weeks prior to the first dose.

5. Use of strong inhibitors or inducers of CYP2C9 or CYP3A4 within 14 days or 5 half-lives (whichever is longer) prior to the first dose.

6. Patients with imaging evidence of brain or central nervous system metastases.

7. Severe bone injury caused by bone metastases of prostate cancer as judged by the investigator.

8. Concurrent uncontrolled hypertension at screening. 9. Presence of active cardiac disease or occurrence of arterial or venous thromboembolism within 6 months prior to the first dose.

10. History of other malignancies within 5 years prior to the first dose. 11. Have active hepatitis B (HBsAg positive and HBV-DNA titer ≥ 1×10³ copies/mL), hepatitis C (HCV antibody positive); or severe infections requiring antibiotics, antiviral or antifungal drugs for control.

12.History of immunodeficiency or organ transplantation. 13.Concurrent dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting drug administration and absorption.

14.Not recovered from adverse events of prior anti-tumor therapy to ≤ Grade 1 at screening.

15.Known allergy to any component or excipient of GLR2037. 16.Subjects who have received palliative radiotherapy or major surgery (Grade 3-4) within 4 weeks prior to the first dose, or have participated in other drug clinical trials within 4 weeks prior to the first dose.

17.Plan to receive any other anti-tumor therapy during the study treatment period other than those specified in the protocol.

18.Any concomitant disease or other condition that, in the judgment of the investigator, poses a serious risk to the safety of the subject or could affect the subject's completion of the study. "

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GLR2037; GLR2037 administered one daily(QD) for 28 day cycles.	Drug: GLR2037; GLR2037 administered QD for 28 day cycles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with Adverse Events as a measure of safety and tolerability of GLR2037	Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 6.0), timing, seriousness, and relationship to study drug.	From signing of informed consent to 30 days after last dose (safety follow-up)
Incidence of DLT of GLR2037	First Cycle Dose limiting toxicities characterized by type, frequency, severity(as graded by NCI CTCAE version 6.0), timing, seriousness, and relationship to study drug	28 Days
Incidence of laboratory abnormalities as a measure of safety and tolerability of GLR2037	Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.	From signing of informed consent to 30 days after last dose (safety follow-up)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of pharmacokinetic (PK) parameter area under the concentration-time curve (AUC).	Concentration-time curve (AUC) for single dose of GLR2037 PK parameters will be assessed when applicable after a single dose and after multiple doses.	At predefined intervals throughout the GLR2037 treatment period, up to last dose of GLR2037
Assessment of pharmacokinetic parameter maximum concentration (Cmax).	Maximum concentration (Cmax) for single and multiple dose of GLR2037 PK parameters will be assessed when applicable after a single dose and after multiple doses.	At predefined intervals throughout the GLR2037 treatment period, up to last dose of GLR2037
Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)	Time to maximum concentration (Tmax) for single and multiple dose of GLR2037 PK parameters will be assessed when applicable after a single dose and after multiple doses.	At predefined intervals throughout the GLR2037 treatment period, up to last dose of GLR2037
To evaluate the clinical anti-tumor activity of GLR2037 in patients with mCRPC	Evaluate PSA in patients in both dose groups	12 Weeks

Collaborators and Investigators

• Sponsor: Gan & Lee Pharmaceuticals.

Study record dates

Study Major Dates

• Study Start (Estimated): April 30, 2026
• Primary Completion (Estimated): October 30, 2031
• Study Completion (Estimated): April 30, 2033

Study Registration Dates

• First Submitted: March 3, 2026
• First Submitted That Met QC Criteria: March 9, 2026
• First Posted (Actual): March 12, 2026

Study Record Updates

• Last Update Posted (Actual): March 12, 2026
• Last Update Submitted That Met QC Criteria: March 9, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Neoplasms
• Other Study ID Numbers: GLR2037-PC-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No